Evidence map›Paper›PMID 38431771›Full record

ReviewMedical science monitor : international medical journal of experimental and clinical research2024

Enhancing Patient Adherence to Newly-Prescribed Medicine for Chronic Diseases: A Comprehensive Review and Cost-Effective Approach to Implementing the New Medicine Service in Community Pharmacies in Poland.

Piotr Merks, Beata Chełstowska, Urszula Religioni, Agnieszka Neumann-Podczaska, Zbigniew Krasiński, Adam Kobayashi, Katarzyna Plagens-Rotman, Ewelina Drelih, Katarina Fehir-Sola, Łukasz Fijałkowski and 8 more

Open access · hybridAbstract readReview
In one paragraph

Review in Medical science monitor : international medical journal of experimental and clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Piotr MerksFaculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland.ORCID 0000-0001-8966-3799
Beata ChełstowskaDepartment of Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland.
Urszula ReligioniSchool of Public Health, Centre of Postgraduate Medical Education of Warsaw, Warsaw, Poland.ORCID 0000-0002-1434-2138
Agnieszka Neumann-PodczaskaChair and Department of Palliative Medicine, Poznań University of Medical Sciences, Poznań, Poland.ORCID 0000-0002-0060-7430
Zbigniew KrasińskiDepartment of Vascular and Endovascular Surgery, Angiology and Phlebology, Poznań University of Medical Sciences, Poznań, Poland.
Adam KobayashiFaculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland.ORCID 0000-0002-0312-6173
Katarzyna Plagens-RotmanCenter for Sexology and Pediatric, Adolescent Gynecology, Division of Gynecology, Department of Perinatology and Gynecology, Poznań University of Medical Sciences, Poznań, Poland.ORCID 0000-0001-7646-7430
Ewelina DrelihThe Polish Pharmacy Practice Research Network (PPPRN), Warsaw, Poland.
Katarina Fehir-SolaEuropean Association of Employed Community Pharmacists (EPhEU), Vienna, Austria.
Łukasz FijałkowskiDepartment of Organic Chemistry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland.
Izabela BajGemini Pharmacies Poland, Gdańsk, Poland.
Regis VaillancourtFaculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland.
Katarzyna Wieczorowska-TobisChair and Department of Palliative Medicine, Poznań University of Medical Sciences, Poznań, Poland.ORCID 0000-0003-4017-3013
Agnieszka Mastalerz-MigasDepartment of Family Medicine, Wrocław Medical University, Wrocław, Poland.ORCID 0000-0001-6600-2760
Mark KoziolPharmacy Defence Association, Birmingham, United Kingdom.
Jarosław PinkasSchool of Public Health, Centre of Postgraduate Medical Education of Warsaw, Warsaw, Poland.ORCID 0000-0002-1015-9643
Filip M SzymańskiDepartment of Civilization Diseases, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland.ORCID 0000-0002-2638-7894
Dagmara HeringDepartment of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland.
Cardinal Stefan Wyszyński University in Warsaw · PLPoznan University of Medical Sciences · PLPostgraduate School of Molecular Medicine · PLCollegium Medicum in Bydgoszcz · PLGdańsk Medical University · PLWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New Medicine Service (NMS) components are an important element to improve patient compliance with medical recommendations. NMS provides support to patients prescribed new medicines, helping them to manage long-term conditions. The purpose of this service is to provide patients with advice, guidelines, and educational materials regarding the use of new medicines to increase patient compliance and therapy safety. The NMS has already been introduced in many European countries. This review aims to identify the benefits and potential barriers to implementing the NMS in community pharmacies and to suggest solutions that would increase its effectiveness. Previous studies have primarily shown that the NMS improves patient compliance with therapy, accelerating the expected effects of the therapy. Pharmacist support during implementation of a new drug therapy substantially increases patient safety. As the experience of numerous countries shows, both pharmacists and patients express positive opinions on this service. Therefore, it seems that NMS should be an indispensable part of pharmaceutical patient care in any healthcare system. This article aims to review the implementation of the New Medicine Service (NMS) for community pharmacists in Poland and the provision of a cost-effective approach to improve patient adherence to newly-prescribed medicine for chronic diseases.

Indexed as

Community Pharmacy ServicesPharmaciesChronic DiseaseCost-Benefit AnalysisHumansMedication AdherencePoland

Identifiers

PMID38431771
PMCPMC10919058
OpenAlexW4391644272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.